STAT48%
STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more 29%
By Ed Silverman71%
7/15/2026, 1:06:40 PM
Keywords: Biogen, Alzheimers Drug, Diranersen, Eli Lilly, Zepbound, Novo Nordisk, Wegovy, Glp 1, Obesity Drug, Frailty, Cognitive Decline
BS Summary: This article contains 8 faulty reasoning types, including Availability Heuristic, Anchoring Bias, and Negativity Bias, with Confirmation Bias as the most egregious example at 32.3% saturation with 102 hits. Analysis detected 310 faulty-reasoning hits from 316 analyzed words, generating a BS Score of 39.2% and a BS Rank of 29% (11,431 of 15,985 articles). This article is better (less manipulative) than 71.50% of the article peer group.
Good morning, everyone, and welcome to the middle of the week.
Congratulations on making it this far, and remember there are only a few more days until the weekend arrives.
So keep plugging away.
After all, what are the alternatives?
While you ponder the possibilities, we invite you to join us for a needed cup of stimulation.
Our choice today is ginseng honey, a favorite from our pantry.
Meanwhile, here is the latest menu of tidbits to help you on your way.
We hope you conquer the world and have a wonderful day.
And as always, please do stay in touch.
…
An experimental Alzheimer’s drug from Biogen, designed with a novel approach, slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved medicines, new data that bolstered the company’s case to move the treatment into a Phase 3 trial, STAT says.
Although experts will wait to see the pivotal trial data before making their final assessments of the drug, called diranersen, the results from the Phase 2 trial, if backed up in the larger study, could rekindle the debate about how strong trial results have to be to signify that a drug can offer meaningful benefits for patients and caregivers.
Potential signs of frailty in older adults taking Eli Lilly’s GLP-1 obesity drug Zepbound may signal relatively high risks for adverse outcomes , Reuters writes, citing a large study that underscores concerns about how best to monitor seniors as U.S.
Medicare expands access to obesity therapies.
In general, frailty-associated conditions such as malnutrition, dehydration and loss of muscle mass and strength developed only rarely and the results should not discourage appropriate use of Zepbound or Novo Nordisk’s GLP-1 drug Wegovy in older adults, the researchers said.
Instead, they encouraged closer follow-up of older patients taking the medicines.
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.